Author Archives: admin


Ricki Lake Opens Up About Her Stunning Hair Transformation and How Sex Is the Best Anti-Ager – NewBeauty Magazine

Last year, Ricki Lake revealed her battle with hair loss on social media after posting an image of herself with a newly-shaved head. The actress and former talk show host had been struggling for more than 30 years with hair damage caused by heavy extensions, years of over styling and yo-yo dieting habits that would trigger yet more hair loss.She says it all started with her iconic role as Tracey Turnblad in the 1988 classic Hairspray.

Although the experience of going public with her condition was freeing for the star, she also worried that her hair wouldnt ever grow back. Lake says prior to shaving it off, she had gone through almost every treatment option, including Rogaine, supplements, spironolactone, steroid shots and platelet-rich plasma injections.

Now, a year later, she is sharing the latest part of her journey that includes a full head of healthy grey hair thanks to the Scandinavian brand Harklinikken, which specializes in hair loss. Here, the star talks about whats happened since she went public and the hair-care routine that has given her a new look and a new hope.

NewBeauty:Before going public with your hair loss journey, what did your day-to-day hair-care routine look like? Ricki Lake:I was wearing a hairpiece, like an extension with bangs in the front. I was living in London for a couple months for a job and the wear and tear of this piece being attached to my hair pulled it and caused it to get more and more frail. I had been on a diet and lost all this weight, so all my hair was shedding and it was just getting heavier on my head. I was supposed to take it off after one month, but I would leave it in for like four or five months because I didnt want to deal with the realityI was in denial.

When the piece came off it was bad. It was right around the holidays, so I bought a wig for $5,000 and only wore it for 15 minutes. I just couldnt wear it. After that, I confided in my boyfriend at the time and shared what was going on. I wouldnt ever let him run his hands through my hair, I was so self-conscious. So, that was the moment for me and I decided to shave it on New Years Day and document it with a photographer friend. I had my closest friends with meand I know it sounds dramatic because its just hair but it was like everything. It was my identity and my femininity, so it was really huge leap to just surrender and take this into my own hands.

NB: What was it like to shave your head. Did you learn anything about yourself or your scalp from the experience? RL:I mean, showering was such a giftI called it orgasmic earlier which is really funny. I hated showering so much before that. I hated getting my head massaged because they would touch me underneath and I was afraid they would feel what was happening. So, to not have to worry about it and to just the positive response I recieved from people that loved how I looked or people who could also relateit just was overwhelmingly positive even though it was about something I was so frightened of. It was really liberating and Ive never looked back. Its been a huge gift of growth for me and Im grateful for it, even the pain.

NB: How has Harklinikken helpedyou regrow your hair? RL:I was skeptical because I tried literally everything. Nine weeks after starting Harklinikken, I went back and we did a before and after of my hair and it was not only growing back, the quality of my hair has improved so much. I have something called androgenetic alopecia, which is so common for so many women. Its basically genetic diffused thinning of my hair through aging and through stress, hormonal birth control, and all the things. And, you know, I can honestly say my hair is in the best shape its ever been. I no longer color my hair. Im embracing my natural gray and silver and Ive been given my life back. It sounds dramatic, but thats truly how I feel.

NB: Yes, its so crazy sometimes how that works. The thing you fear the most, once youve gone through it, its sometimes the thing that helps you progress the most. RL:Yes, and its been true in other areas of my life, like you know I lost my husband almost four years ago to suicide and mental illness, and that was a gift too. Obviously losing my partner was the worst thing that ever happened to me, but then its through time and through the process of healing that you see the gifts that come out of that, like loving myself in the way that he loved me. For a long time, I didnt value myself enough. Losing him and knowing how much he loved me, I now do value myself and that has led me to the relationship Im in now. So, all of it is like this journey that we go on and these trials and tribulations that lead us to a better place hopefully.

NB: Is there any advice you would give to a younger you if you could? RL:I wouldnt have taken hormonal birth control. I would have stopped the yo-yo dieting and the self-loathing. I mean I just I beat myself up so much. I think so much of this has to come with age. You know people often say it and I didnt believe it to be true, but now I do see that when you turn 50 you dont really care what people think. What people think of me is none of my business. So, I definitely would have been kinder to my younger self if I had the opportunity.

NB: How has your approach to skin care and anti-aging changed from decade to decade? Is there anything youre doing now that you swear by? RL:Not really, I mean I get a lot of sleep I take really good care of myself. I eat well. I have a really active sex life. I mean I feel like Im in my sexual prime and my partner would agree. Im lucky that I do not have wrinkles! Im 52 and I think its purely genetic. I would get a facial every couple of months, but I dont anymore because of COVID. I used to get fake eyelashes and I dont even do that anymore!

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

Read the original post:
Ricki Lake Opens Up About Her Stunning Hair Transformation and How Sex Is the Best Anti-Ager - NewBeauty Magazine

Why Hair Goes Gray, and How to Cover It If You Want To – NewBeauty Magazine

For many women, salon closures and stay-at-home orders meant embracing their gray strands after decades of dye; for others, it meant hours of research about at-home hair color, root cover-ups, and lots of really cute headbands.

Lets get into the science behind it: As hair is being formed, melanocytes inject pigment into keratinocytesthe cells containing keratinwhich is the protein making up hair, skin and nails, says Wayne, NJ plastic surgeon and hair specialist Jeffrey B. Wise, MD. Over time, melanocytes continue to inject pigment into the hairs keratin, which is where hair gets its color. In the aging process, melanocytes slow down and eventually stop secreting melanin, which causes a lack of pigment, and the hair turns gray.

According to Chicago dermatologist Dr. Quenby Erickson, going gray is programmed in our genetic code, which means we can get clues as to how extensively and when it will happen by looking at our parents. However, a 2020 study published in Science Daily shows there may also be a link between stress and gray hair. When testing on mice, researchers found that the type of nerve involved in the fight-or-flight response causes permanent damage to the pigment-regenerating stem cells in the hair follicle. The study makes perfect sense, says Dr. Wise. Stress is a huge factor in premature aging, as well as hair thinning. Naturally, it should also affect hair graying as well. There is also a lot of evidence that shows smoking cigarettes plays a role in making hair go gray earlier.

Color isnt always the only factor either; textural changes can ensue as well. Some people are blessed with gorgeous gray hair, but for most of us, the gray is accompanied with thinning and rougher texture that leave our hair finer and harder to style, Dr. Erickson says. There are no proven ways to prevent hair from turning gray, but both Drs. Erickson and Wise have seen some promising results from platelet-rich plasma (PRP) injections. Because these treatments are aimed at waking up your own stem cells, they could potentially reinvigorate melanocyte production as well, explains Dr. Wise. We have seen growth of darker, thicker hairs on some of our stem cell therapy patients, even though the original goal was to combat thinning. Treatment results are dependent on the patients individual conditions, so realistic expectations should be set by your doctor.

Celebrity colorists Chad Kenyon and Rita Hazan say none of their clients embraced their grays during quarantine, or they tried, but caved eventually. For those in camp cover them up, topical dyes and root concealers can help camouflage. The process to cover gray hair is the same on both blonds and darker shades, but my clients with lighter hair can go longer in between touch-ups because gray hairs blend with blond hairs more easily, says Kenyon. Celebrity colorist Aura Friedman often suggests adding a darker pepper tone to silver hair for people who feel more comfortable being darker, but dont want the two-, three- or four-week regrowth touch-up thats needed.

For those who want to permanently cover their grays at home, Nikki Lee, celebrity colorist and cofounder of Nine Zero One Salon, recommends Garnier Nutrisse Nourishing Color Creme ($8). There are more than 75 shades and you can easily find your match using a virtual shade selector, she says. If DIY color makes you nervous, temporary root sprays are great to use in between salon appointments.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

Read more:
Why Hair Goes Gray, and How to Cover It If You Want To - NewBeauty Magazine

Healthcare Inventory Management Market: Rising Research and Development is Anticipated to Drive the Market – BioSpace

Global Healthcare Inventory Management Market: Overview

Global Healthcare Inventory Management Market: Notable Developments

Some of the notable developments in the global healthcare inventory management market include:

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=70833

Global Healthcare Inventory Management: Drivers and Restraints

The following are the factors that act as drivers and restraints in the global healthcare inventory management.

Request for Analysis of COVID-19 Impact on Healthcare Inventory Management Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=70833

Optimum Efficiency to Promote Global Healthcare Inventory Management

Inventory management saves time in tracking devices and equipment that are needed for patient. This results in optimum efficiency and more time for patient care, owing in the expansion of the global healthcare inventory management market. The tacking system uses GPS and RFID (Radio Frequency Identification) technologies to identify the inventory.

Additionally, if the equipment, devices, and medicines are not available on time, this could be fatal at times. Therefore, the demand for the inventory management is high due to large pool of patients seeking medical care; this is leading to the growth opportunities in the global healthcare inventory management market.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=70833

Minimal Investment to Bolster Demand

Surgical devices and equipment are of high value and are not replaced often. If not managed properly it may go missing while handling them and result in high investment to acquire new equipppment. However, this is where inventory management comes handy in maintaining them, pushing the growth of the global healthcare inventory management market in upcoming years.

Further, the inventory management helps in stock taking and stock piling. It also helps in keeping a track of expired or obsolete stock. Additionally, it helps in minimizing the spreading of infections and diseases by stocking and sterilizing of devices and medical equipment. This reduces the chances of spreading of infection and diseases, aiding in the grandiose growth of the global healthcare inventory management over the forecast period.

Rapid technological advancements and rising research and development are also anticipated to drive the inventory management market. Mobile devices with longer battery life are expected to speed up the tracking process. Further, inventory tracking can reduce the cost of labor, aiding in the expansion of the global healthcare inventory management market.

Pre Book Healthcare Inventory Management Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=70833&ltype=S

Global Healthcare Inventory Management Market: Geographical Analysis

Previously, North America dominated the global healthcare inventory management market. The growth can be due to the presence of technological advancement, better medical infrastructure, and presence of large number of hospitals and research labs.

Asia Pacific is projected to witness an impressive boost in the global healthcare inventory management market. The growth in this region can be attributed to factors such as rapid industrialization and urbanization, improvement in medical infrastructure, and technological advancement.

Browse More Reports by Transparency Market Research:

Stool Management Systems Market: https://www.transparencymarketresearch.com/stool-management-systems-market.html

Adipose Derived Stem Cell Therapy Market: https://www.transparencymarketresearch.com/adipose-derived-stem-cell-therapy-market.html

Severe Combined Immunodeficiency Treatment Market: https://www.transparencymarketresearch.com/severe-combined-immunodeficiency-treatment-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/

See more here:
Healthcare Inventory Management Market: Rising Research and Development is Anticipated to Drive the Market - BioSpace

Cell and Gene Therapy Firms Gear up to Revolutionize Manufacturing – Labiotech.eu

With the rising demand for cell and gene therapies, the need for manufacturing innovation has never been higher. A surge of deals and expansions in the last year is fuelling the push to truly make these therapies widely available and affordable.

Cell and gene therapies offer huge potential to treat a wide range of diseases including cancer, neurological, and genetic diseases. They have even shown promise to treat the symptoms of Covid-19.

The amount of academic and early-stage biotech research in this area has skyrocketed over the last few years. According to the Alliance for Regenerative Medicine, there are currently 1,220 ongoing clinical trials in this space, 152 of which are at phase III. Despite the global pandemic, investment in this area is also at a record high around the world, with the equivalent of 15.7B invested in 2020, a figure double that of 2019.

But research alone cannot get these complex treatments to patients. The sharp discrepancy between the high number of products in early-stage development and the still very small number that have made it onto the market, as well as their cost, speaks to the impact and importance of cost-effective and scalable manufacturing, Ryan Cawood, CEO of Oxgene (previously Oxford Genetics), told me. Oxgene is a UK biotech aiming to improve manufacturing for cell and gene therapies.

To meet this challenge, cell and gene therapy producers are exploding into motion. With 2021 only just getting started, weve seen manufacturing deals between Vigeneron and Daiichi Sankyo, Sirion Biotech and Cellectis, and Cevec and Biogen. The giant Thermo Fisher Scientific absorbed the Belgian viral vector producer Henogen for 724M. And CDMO heavyweights like Cognate BioServices and Polyplus Transfection have announced expansions to their manufacturing capacity.

Thedifficulties with manufacturing the recently approved Covid-19 mRNA vaccines in high enough quantities has really highlighted the importance of having a solid manufacturing strategy in place. This lesson applies equally to companies trying to take cell and gene therapies to market.

Stuck in the first generation

Despite the huge increase in development of cell and gene therapies over the past couple of years, manufacturing technology for these therapies is largely still at the first-generation stage. This can make scaling up a challenge.

Often cell and gene therapy manufacturing processes are highly manual stemming from the early academic or process development stage and, without adequate technology solutions available currently, these processes often remain this way through clinical trials and then into commercial manufacturing, said Jason Foster, CEO of Ori Biotech, a London- and New Jersey-based company focusing on cell and gene therapy manufacturing.

These first-generation processes cause manufacturing to be expensive, highly variable and low-throughput, which reduces the ability of patients to access these potentially life-saving therapies.

Another problem common to all bio-based therapeutics is that any product sourced from a live cell or a component of one is subject to a lot more variation than a simpler pharmaceutical product.

Most gene therapies are built on viruses found in nature. They have not evolved for very high productivity in a large-scale, animal component-free bioreactor, said Cawood.

The more complicated the biologic becomes, the more parts of it require optimization, and the more analytics you require.

According to Kevin Alessandri, the cofounder and CEO/CTO of the French company TreeFrog Therapeutics, there is also a lot of waste in cell therapy manufacturing.

Yields are impaired by high cell death at every passage, and genetic alterations inevitably arise, said Alessandri. When it comes to producing commercial batches to treat thousands of patients, scaling out 2D cell culture processes is far too expensive and poses batch-to-batch reproducibility issues.

While many in the industry are now turning to bioreactors to produce cells on a bigger scale, this is also not without problems. Impeller-induced shear stress is damaging the cells, thus negatively impacting cell viability and triggering undesired genetic mutations, explained Alessandri.

Taking manufacturing up a gear

What are companies in this space doing to make scaling up cell and gene therapies easier, quicker, and cheaper?

Ori Biotech raised24.8M in Series A funding in October last year to develop an automated and robotic manufacturing system to minimize the number of manual steps needed to produce a given cell or gene therapy. This speeds up the process as well as making it more accurate. Another advantage of the technology is that it can tailor the production capacity according to demand.

This is impossible to do in most current processes, which involve manual tube welding and transfers from flask to bag to bigger bag to bioreactor, said Foster, adding that this increases cost and variability while constraining throughput. Oris technology, in contrast, could take years off the production timeline and cut costs by as much as 80%.

London-based Synthace is one of several companies trying to improve advanced therapeutic manufacturing by developing software and computer systems to optimize the process, rather than industrial machinery.

Peter Crane, Corporate Strategy Manager for the company, said that in-depth data analysis and planning before starting the manufacturing process can make a big difference to outcomes, and that connected software can help make this task easier.

The best way to remove some of the risk associated with biomanufacturing of these products is to solve as many problems as possible before manufacturing.

In addition to making the process quicker, cheaper, and more accurate, computing tools can also help with quality control and tracking. In cell therapy manufacturing, especially autologous products, line of sight around electronic batch records, as well as the vein-to-vein supply chain, is incredibly important, emphasized Crane.

Another company specifically focusing on logistics and quality control is the Cardiff- and San Francisco-based TrakCel, which nailed deals with Ori Biotech in February and the UKs National Health Service in November.

The company TreeFrog Therapeutics works with cell encapsulation technology to improve quality and reduce waste, albeit from a more mechanical viewpoint. The company launched an industrial demonstration plant in June last year, followed by two co-development deals with undisclosed big pharma partners.

Encapsulated stem cells spontaneously self-organize in an in vivo-like 3D conformation promoting fast and homogeneous growth, as well as genomic stability, said Alessandri. The resulting 3D stem cell colony can then be differentiated in the capsule into functional microtissues ready for transplantation.

With our technology, which is based on high-throughput microfluidics capable of generating over 1,000 capsules per second, it becomes possible to expand and differentiate stem cells at a large scale, in industrial bioreactors, with best-in-class cell quality and reduced operating costs.

Oxgene has a focus on scaling up production for manufacturers. In September, the company launched a technology to scale up manufacturing of viral vector production with less contamination and a 40-fold improvement in yield compared to current methods. Oxgenes expertise with viral vectors also prompted a collaboration deal in April with the CDMO Fujifilm Diosynth Biotechnologies.

Innovation in new manufacturing technologies just hasnt kept pace with the level of discovery around genetic disease and potential avenues open to treat them, or even development of the viral vectors themselves, said Cawood. This is definitely changing though.

Enter the second generation of manufacturing

Cell and gene therapy manufacturing is definitely hot right now, boosted by increased needs from biotech and pharma companies developing Covid-19 vaccines and therapies, and by notable increases in investment.

Huge advances in gene and cell therapies over the last few years, such as the approval of the eye gene therapy Luxturna and the first CAR T-cell therapies, mean the demand for new manufacturing technologies has also increased exponentially.

A lot of very promising programs are now in the pipeline, and patients are waiting for their approval, said Alessandri. Industry urgently needs robust manufacturing technology, capable of serving millions of patients.

European biotechs are busy developing second-generation technologies to allow easier and cheaper scale up, producing higher quality products with less waste. They could start to phase out first-generation methods very soon.

The realm of cell manufacturing in industrial and food biotech is also likely to see big breakthroughs in the coming years. Earlier this month, for instance, the nutrition and health giant Royal DSM set up a lab in the Netherlands dedicated to applying artificial intelligence (AI) to the challenge of growing microbial strains at a commercial scale.

Rapid improvements in advanced computing options such as AI and machine learning technology, as well as robotics, are already having an effect on the industry, but this will only get bigger as time goes on.

Cover image from Elena Resko. Body text image from Shutterstock

More:
Cell and Gene Therapy Firms Gear up to Revolutionize Manufacturing - Labiotech.eu

Latest Research and Industry Trends of Cell and Tissue Culture Supplies Market Forecast 2027 Stemcell Technologies, Wheaton Industries, GE Healthcare …

Overview Of Cell and Tissue Culture Supplies Industry 2021-2027

The Cell and Tissue Culture Supplies Market Report a definite study of various parts of the Worldwide Market. It shows the consistent development in market regardless of the variances and changing business sector trends. The report depends on certain significant boundaries.

In 2020, the world faced a public health emergency because of the COVID-19 outbreak. Several industries were severely affected because of multiple lockdowns and disruptions in the supply chains. The semiconductor and electronics industry is among the most affected industries owing to its high dependence on China and other severely hit economies. However, the industry bounced back robustly in the second half of 2020.

The Top key Players in Cell and Tissue Culture Supplies Industry include are:- , Stemcell Technologies, Wheaton Industries, GE Healthcare, Thermo Fisher Scientific, VWR International, Merck KGaA, Lonza Group, Corning, Promocell GmbH, Eppendorf AG,

Get a Sample PDF copy of this Cell and Tissue Culture Supplies Market Report @:https://garnerinsights.com/Global-Cell-and-Tissue-Culture-Supplies-Market-Trends-By-Regional-Analysis-America-Europe-Asia-Pacific-and-Middle-EastAfrica-Growth-Opportunity-and-Industry-Forecast-2021-2027#request-sample

The study gives a transparent view on the Global Cell and Tissue Culture Supplies Market and includes a thorough competitive scenario and portfolio of the key players functioning in it. To get a clear idea of the competitive landscape in the market, the report conducts an analysis of Porters Five Forces Model.

Major Product Types covered are: , Consumable Products, Instruments,

Major Applications of Cell and Tissue Culture Supplies Market covered are: , Vaccine Production, Biopharmaceutical Production, Toxicity Testing, Gene Therapy, Drug Screening & Development, Cancer Research, Others,

The researchers and analysts have provided in-depth analysis of theCell and Tissue Culture Supplies market segmentation based on the type, application, and geography. The report also sheds light on the vendor landscape, in order to inform the readers about the changing dynamics of the market.

Some of the major geographies included in the Cell and Tissue Culture Supplies market are given below: North America (U.S., Canada) Europe (U.K., Germany, France, Italy) Asia Pacific (China, India, Japan, Singapore, Malaysia) Latin America (Brazil, Mexico) Middle East & Africa

To get this report at a profitable rate.https://garnerinsights.com/Global-Cell-and-Tissue-Culture-Supplies-Market-Trends-By-Regional-Analysis-America-Europe-Asia-Pacific-and-Middle-EastAfrica-Growth-Opportunity-and-Industry-Forecast-2021-2027#discount

The objectives of the study are as follows:

.

Scope of the Report:- The report scope consolidates a nitty gritty examination of Worldwide Cell and Tissue Culture Supplies Market 2021 with the apprehension given in the headway of the business in specific regions.

The Top Organizations Report is intended to contribute our purchasers with a preview of the business most persuasive players. In addition, data on the exhibition of various organizations, benefit, net edge, vital activity and more are introduced through different assets, for example, tables, diagrams, and information realistic.

About Garner Insights: Garner Insights is a Market Intelligence and consulting firm with a comprehensive experience and rich knowledge of theCell and Tissue Culture Supplies Market research industry. Our vast repository of research reports across various categories, gives you a complete view of the ever-evolving trends and current topics worldwide. Our constant focus is on improving the data and finding innovative methods, which will help your business drive profitable growth.

Contact Us Kevin Thomas Email: sales@garnerinsights.com Contact No: +1 513 549 5911 (US) | +44 203 318 2846 (UK)

Read the rest here:
Latest Research and Industry Trends of Cell and Tissue Culture Supplies Market Forecast 2027 Stemcell Technologies, Wheaton Industries, GE Healthcare ...

5 People in the BioHealth Capital Region You Should Know In 2021 – BioBuzz

2020 brought about a lot of growth across the BioHealth Capital Region (BHCR) as dozens of organizations responded with urgency to address the COVID-19 pandemic. With 20% of the worlds vaccine leaders residing in the region, the BHCR has played a critical role in the pandemic response. In Maryland, nearly $8 Billion in federal, private, and foundational funding has been invested in life sciences companies for coronavirus vaccine research and other immunotherapeutic developments.

The past year has seen several new leaders step into roles that will impact our biotech ecosystems growth and direction. Just as we highlighted 2020s new leaders in the BHCR, we want to recognize the people in the Biohealth Capital Region that you should know in 2021

These new leaders are sure to help the many companies across our region raise capital, establish their growth plans, attract new talent, build collaborations, and help attract even more companies to our diverse ecosystem. Diversity is one of Marylands greatest assets.

So, who are these people you should know in BHCR in 2021?

Weve identified five new faces that we believe will play prominent roles that will influence and shape the future of the BHCR.

Ulyana Desiderio joined the Department of Commerce in April 2020 as Director of BioHealth and Life Sciences. She leads efforts that support Marylands life sciences communitys growth, including job creation, capital investment, and new business formation. In 2020 she jumped right in and joined the BioHealth Capital Region Planning Committee, held virtually last October.

Before joining Commerce, Desiderio served as Chief Scientific Officer for the American Society of Hematology, the largest international medical association dedicated to blood diseases. Ulyana holds B.S. degrees in Biological Sciences and Chemistry from Drexel University and a Ph.D. in Biochemistry from the Johns Hopkins University Bloomberg School of Public Health.

She loves her role as a public servant for the states life science industry and is committed to ensuring that companies thrive and prosper in Maryland. Desiderio shares that there is so much innovation to keep up with. It makes my work in business attraction easy the Why Maryland story practically tells itself and I dont get tired of telling it. Maryland biotech companies can be assured that they have a staunch advocate at the Department of Commerce who is ready to help them succeed and get their innovative and life-saving products to market.

In September 2020, TEDCO, Marylands economic engine for technology companies, appointed Troy LeMaile-Stovall as Chief Executive Officer and Executive Director. Troy has over 25 years of experience in investment management, higher education, telecommunications, information/communication technology, management consulting, and non-profit leadership/management.

Troy took over leadership at TEDCO following Interim CEO and Executive Director Linda Singh, who led the organization during the search. When asked about his long-term vision for TEDCO, LeMaille-Stovall said, the long-term vision is no different than what it is today with one-word change. The change is to move from economic development to economic empowerment. If youve watched the new TEDCO Talks interview series, you may have heard part of LeMaile-Stovalls strategy to get there is by creating an ecosystem where the degrees of separation between any two people, and any two organizations has been minimized.

TEDCO plays a crucial role as Marylands innovation intermediary and provides commercialization and early-stage funding through a series of funding vehicles aligned to invest in the States various innovation assets, including Stem Cell Research, University technology, economically disadvantaged entrepreneurs, rural entrepreneurs, and federal tech transfer. LeMaille-Stovall will no doubt play an important role in Marylands ecosystem reaching its greatest potential.

Joe took over as Director, R&D Science Engagement in August of 2020 after five years with the company. He first joined AstraZeneca in November 2015 as a Learning & Talent Development Business Partner supporting their commercial biomanufacturing site in Frederick, MD. There, he led the strategic business unit through the successful global regulatory defense to support (3) commercial product launches and multiple clinical entities.

In his new role, Joe is leading AZs efforts to build new partnerships and is spearheading their Science, Technology, Engineering, and Mathematics (STEM) workforce development programming across the U.S. Sanchez will be a highly visible driving force behind greater ecosystem cooperation and more robust workforce development programming. Increasing regional engagement among industry, government, and academia, as well as delivering enhanced STEM programming across Maryland, Virginia, and Washington, DC, are critical components to furthering the regions biohealth cluster strategy and elevating the BHCR brand.

Dr. Anne Khademian, a Presidential Fellow and professor at Virginia Tech, has been appointed executive director of the Universities at Shady Grove (USG) in September 2020. The University System of Maryland (USM) regional higher education center offering undergraduate and graduate degree programs from nine USM institutions at its campus in Rockville, Md.

With more than 20 years in higher education, Khademian is a nationally recognized scholar and author in inclusive leadership and organizational change. Khademian is a fellow and member of the Board of Directors of the National Academy of Public Administration, an independent, nonprofit, and nonpartisan organization established by Congress to help government leaders build more effective, efficient, accountable, and transparent organizations.

With programs such as UMBCs TLST (2020 BioBuzz Workforce Champion Award Winner), which is designed with industry input that produces undergraduates with a workforce ready degree, and other biotech workforce development initiatives, Dr. Khademian and USG will play a vital role in the growth of our current and future workforce.

Just over a year ago, Brad Stewart joined MCEDC as their Senior Vice President, Business Development, following his role as CEO of Immunology Partners (IPI). Before IPI, Brad was CEO of Cylex. Using his years of experience as a serial entrepreneur, Brad heads up a team of economic development specialists focused on growing biohealth companies and other industries from technology to hospitality in Montgomery County (MoCo).

MoCo is the epicenter of the BioHealth Capital Regions global biotech and life science cluster and home to 300+ Bio companies and 40,000 Biotech workers. MoCo is located within MDs 8th Congressional district, where STEM workers are triple the national median. The district also leads the nation in the proportion of science and engineering jobs to total workforce.

In Stewards role, he will continue to grow MoCos biotech ecosystem and attract more companies like On-Demand Pharmaceuticals, which recently selected Montgomery County, Maryland for its new GMP manufacturing, research, development, and headquarters facility. Steward also chairs Maryland Life Sciences (MD Bio) and is the Vice-Chair of the Maryland Tech Council, where he can impact biotech and tech companies across the State.

Learn more about the scientists, leaders, and innovators who make up the BioHealth Capital Region by exploring our sites People section.

Andy has worked with BioBuzz for the last decade to help spread the word of the BioHealth Capital Region even before it was branded with that name. His background includes years at MedImmune supporting the Commercial Operations Organization before becoming a BioHealth Nomad working with various clients in Operations, Communications and Strategic Services.

Read more here:
5 People in the BioHealth Capital Region You Should Know In 2021 - BioBuzz

Global CAR-T Therapy Market Opportunities and Strategies Report 2020: COVID-19 Impact and Recovery – Forecast to 2030 – GlobeNewswire

January 28, 2021 09:03 ET | Source: Research and Markets

Dublin, Jan. 28, 2021 (GLOBE NEWSWIRE) -- The "CAR-T Therapy Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.

The global CAR-T therapy market reached a value of nearly $734.0 million in 2019. The market is expected to grow from $734.0 million in 2019 to $2,250 million in 2023 at a rate of 32.3%. The growth is mainly due to an increased prevalence of cancer and increased awareness about the therapy. The market is expected to stabilize and reach $3,150 million in 2025 and $6,100 million in 2030.

The CAR-T therapy market consists of sales of CAR-T therapy products and related services by entities (organizations, sole traders and partnerships) that develop chimeric antigen receptor (CAR) T-cell therapies to treat all types of cancers. This industry includes establishments that are involved in the research and development to introduce new targeted cell therapies for treating different blood related cancers.

Growth in the historic period resulted from increases in healthcare expenditure, increase in pharmaceutical R&D expenditure and advances in drug discovery. This growth was restricted by low rate of drug approvals, challenges due to regulatory changes and limited number of treatment centers.

Going forward, increase in blood cancer incidence rate, rise in healthcare expenditure, strong pipeline of drugs and rising focus on car-t therapy are expected to drive the market. High costs of therapy, reimbursement challenges, adverse events, complex manufacturing and supply chain and covid-19 impacting drug trails, and reduction in free trade are major factors that could hinder the growth of the CAR-T therapy market in the future.

The CAR-T therapy market is segmented by target antigen into CD19, CD22, BCMA and others. The CD19 was the largest segment of the CAR-T therapy market by target antigen, accounting for 100% of the total market in 2019. Going forward, CD19 segment is expected to be the fastest growing segment in the CAR-T therapy market, at a CAGR of 25.3%.

The CAR-T therapy market is also segmented by application into acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma and others. The diffuse large B-cell lymphoma was the largest segment of the CAR-T therapy market by application, accounting for 56.1% of the total market in 2019. Going forward, the others segment is expected to be the fastest growing segment in the CAR-T therapy market, at a CAGR of 29.3%.

North America was the largest region in the global CAR-T therapy market, accounting for 60.3% of the total in 2019. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the CAR-T therapy market will be Asia Pacific and Western Europe, where growth will be at CAGRs of 85.1% and 32.4% respectively.

The CAR-T therapy market is particularly prone to disruption from the coronavirus outbreak, as patients with cancer are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgeries. COVID-19 has caused clinical trial delays for CAR-T therapy drugs. Due to worldwide lockdown, production is also being halted which is causing supply chain issues.

The CAR-T therapy market is concentrated, with a small number of large of large players in the market. Major players in the market include Novartis AG and Gilhead Pharmaceuticals.

The top opportunities in the CAR-T therapy market segmented by target antigen will arise in the CD19 segment, which will gain $1,077.3 million of global annual sales by 2023. The top opportunities in the CAR-T therapy market segmented by application will arise in the diffuse large B-cell lymphoma segment, which will gain $738.5 million of global annual sales by 2023. The CAR-T therapy market size will gain the most in the USA at $744.9 million.

Market-trend-based strategies for the CAR-T therapy market include focus efforts towards investing in the R&D for creating remodeled CAR-T therapy to avoid neurological side-effects, creating off-the-shelf allogeneic CAR-T therapy for advanced cancer treatment, manufacturing next-generation CAR T cells for improved treatment of high-grade glioma, investing in AI and machine learning solutions to optimize future CAR-T therapy, carrying out strategic collaborations to boost innovations, collaborating or acquiring competitor companies to expand CAR-T therapy portfolio, and investing in the CAR-T therapy to make it more effective. Player-adopted strategies in the CAR-T therapy market include expansion through mergers and acquisitions, and strategic partnerships with technology companies.

To take advantage of the opportunities, the publisher recommends the CAR-T therapy companies should consider collaborating or acquiring competitor companies, invest in machine learning and artificial intelligence, next-generation car-t cells, competitive pricing, expanding in emerging markets, set up authorized distributors and sales representatives, leverage e-commerce to maximize reach and revenues, increasing adoption of internet, attending business events, targeting community oncologists/hematologists, and collaboration with treatment centers.

Key Topics Covered:

1. CAR-T Therapy Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction 6.1.1. Segmentation by Geography 6.1.2. Segmentation by Application 6.1.3. Segmentation by Target Antigen

7. CAR-T Therapy Market Characteristics 7.1. Market Definition 7.2. Market Segmentation by Target Antigen 7.2.1. CD19 Therapy 7.2.2. CD22 Therapy 7.2.3. BCMA Therapy 7.2.4. Others 7.3. Market Segmentation by Application 7.3.1. Acute Lymphoblastic Leukemia 7.3.2. Diffuse Large B-Cell Lymphoma 7.3.3. Follicular Lymphoma 7.3.4. Chronic Lymphocytic Leukemia 7.3.5. Multiple Myeloma 7.3.6. Others

8. CAR-T Therapy Market Customer Information 8.1. Interest of Physicians 8.2. Positive Perception of Community Oncologists Towards CAR-T Therapy 8.3. Challenges and Perceived Barriers in the Adoption of CAR-T Therapy by Community Oncologists 8.4. Improvement in Quality of Life After CAR T-Cell Therapy

9. CAR-T Therapy Market Trends and Strategies 9.1. Remodeled CAR-T Cell Therapy for Fewer Side Effects 9.2. Off-The-Shelf Allogeneic CAR-T Therapy for Improved Treatment 9.3. Next-Generation CAR-T Cells for Treatment of High-Grade Glioma 9.4. Machine Learning and Artificial Intelligence to Optimize Future CAR-T Therapy 9.5. Collaborating with Technology Companies for Advanced Technologies 9.6. Growing Partnerships for Promoting CAR-T Therapy Market

10. CAR-T Therapy Market, COVID Impact Analysis 10.1. Impact on Global CAR-T Therapy 10.2. Impact on Global CAR-T Therapy Clinical Trials 10.3. Impact on Leading Global Oncology Companies

11. Global CAR-T Therapy Market Size and Growth 11.1. Historic Market Growth, 2015 - 2019, Value ($ Million) 11.1.1. Drivers of the Market 2015 - 2019 11.1.2. Restraints on the Market 2015 - 2019 11.2. Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million) 11.2.1. Drivers of the Market 2019 - 2023 11.2.2. Restraints on the Market 2019 - 2023

12. Global CAR-T Therapy Market Segmentation 12.1. Global CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million) 12.1.1. Diffuse Large B-Cell Lymphoma 12.1.2. Acute Lymphoblastic Leukemia 12.1.3. Follicular Lymphoma 12.1.4. Multiple Myeloma 12.1.5. Chronic Lymphocytic Leukemia 12.1.6. Others 12.2. Global CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million) 12.2.1. CD19 12.2.2. BCMA 12.2.3. Other Target Antigen 12.2.4. CD22

13. CAR-T Therapy Market, Regional and Country Analysis 13.1. Global CAR-T Therapy Market, by Region, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million) 13.2. Global CAR-T Therapy Market, by Country, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/4e45uj

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the original post:
Global CAR-T Therapy Market Opportunities and Strategies Report 2020: COVID-19 Impact and Recovery - Forecast to 2030 - GlobeNewswire

Their Goal: Meat That’s Better Than Meat | Tufts Now – Tufts Now

There are plenty of reasons to want to shift away from eating meat: its better for the planet and certainly better for animals that would otherwise be eaten. But meat is still a big draw, both in the U.S. and increasingly in medium-income countries like China.

At the Tufts School of Engineering, a team of scientists led by Professor David Kaplan is exploring another avenue to feed this trendmeat grown directly from animal cells. It could be the start of an entirely new agricultural industryas humane and green as plant-based meat substitutes, but providing taste, texture, and nutrition that is even closer to the experience of eating real meat.

The technology is already familiar to cell biologistsgrowing and harvesting cells from a single sample of tissue from a live anesthetized animal, but doing it in ways that may help the cells transform into something similar to the muscle tissue people enjoy eating from beef, chicken, and fish, including shrimp and scallops.

Meat from animals contains connective tissue, vascular networks, fat, and other cell types, as well as blood, biological fluids, and a complex mix of proteins and sugars, all of which contribute to the unique taste and texture of the meat. Replicating that structure and content is the technical challenge that the Tufts team is working on using the tools of tissue engineering.

A variety of flavors and textures can be achieved by growing different types of cells together, like skeletal muscle, fat cells and fibroblasts (the most common type of cell in connective tissue), adding nutrients to the surrounding media (the soup in which the cells grow), or using genetic modification to add components that not only introduce flavors, but can modify color or even improve on the nutritional quality of natural meat.

Andrew Stout, a doctoral student in biomedical engineering, has explored adding myoglobin to the cell growth media, for example. Myoglobin, a natural component of muscle, is a protein that carries iron and oxygen, and is associated with the bloody flavor of meat. He found that its addition to the mix helps improve the color of the cell mass, and even enhanced the growth rate of the meat substitute.

Stout has also been working to enhance the nutritional content of cell-based meat. In a recent journal publication, he reported how he had modified muscle cells from cows by genetically adding enzymatic machinery to produce the antioxidants phytoene, lycopene, and beta-carotene, normally found in plants.

Think of it as a way to make cell-based meat more plant-like in the healthy nutritional components it offers. Adding beta-carotene, for example, could have protective effects against colorectal cancer, which tends to be more prevalent among those with a high intake of red meat. Another benefit of this type of metabolic engineering is that the antioxidants could improve the quality and shelf-life of the meat.

How far can they take this nutritional engineering? I think other nutrients would definitely work, said Stout. Thats one of the things that I am the most excited about. Putting plant genes into mammalian cells is pretty un-travelled scientific territory, and so theres a lot of space to explore other nutrients, flavor, and color compounds. In addition, he adds, the cell-based meat can be engineered as a therapeutic food.

Most cell-based approaches have emulated processed meat such as hamburger, sausage, and nuggets. Replicating the appearance and texture of whole cuts of meat, like steak, is a different kind of challenge.

Tissue engineering experts in the Kaplan lab bring a lot of experience to the task of aligning cells and creating fibers resembling real meat structure, using things like mechanical tension and micropatterned substrates to help align cells into fibers.

Natalie Rubio, a Ph.D. student in biomedical engineering, found that switching from cows to caterpillars as a source of cells can have some advantages. The muscle and fat stem cells originating from the eggs of the tobacco hornworma beefy little caterpillarcan be used to generate tissue that resembles other invertebrates that were used to eating, like shrimp and scallops.

A vast amount of knowledge has already developed around large scale invertebrate cell culture, since insect cells are widely used in the production of pharmaceuticals. Suspended in a liquid medium, they tend to grow to very high density and have simpler requirements for maintenance and growth. Yields could be greater and production costs lower than from mammalian cells.

But Rubio explains that there is a very important step remaining to transform a soup of cells into something resembling real meatproviding a scaffold to shape and orient the cells.

The scaffold is the backbone of the meatit provides structure and texture, said Rubio. If we did not have that support structure, the meat would just look like slime.

Rubio generates scaffolds from chitosana polymer found in a closely related form (chitin) in exoskeletons such as crab shells and fungi. Chitosan is a great material to make scaffolds from because it is edible, abundant, and inexpensive, she said.

Chitin can be isolated from fungi and easily converted to chitosan and then formed into films, fibers, or sponges to act as scaffolding for cell culture. Rubio grows insect muscle and fat cells on the chitosan scaffolds to generate small, structured meat constructs.

Kaplans lab has been a hub and catalyst for cellular agriculture research and development in the academic sector for many years, he said. That continues with an annual course for undergraduates on cellular agriculture, which is again being offered this spring semester.

Cell-based meat has not yet been commercialized, but the first cultured beef burger was produced by Maastricht University in 2013, and a number of start-up companies are now working to create new products to sell.

Alumni from our group have fanned out across the globe to help create the foundation of a nascent cell-based agricultural industry, Kaplan said. They include Laura Domigan, who is a principal investigator at University of Auckland; research scientist Amanda Baryshyan at Gloucester Marine Genomics Institute; Ryan Pandya, CEO of Perfect Day Foods; Viktor Maciag, head of tissue engineering at Mission Barns; and Robin Simsa, CEO of Legendary Vish.

Mike Silver can be reached at mike.silver@tufts.edu.

Read the original here:
Their Goal: Meat That's Better Than Meat | Tufts Now - Tufts Now

Cell and Gene Therapy Market Size to Reach USD 7,250.0 Million by 2028 | Increasing Investments in Production Capacity Expansion for Cell and Gene…

January 26, 2021 05:38 ET | Source: Emergen Research

Vancouver, British Columbia, Jan. 26, 2021 (GLOBE NEWSWIRE) -- The global cell and gene therapy market is projected to reach a market size of USD 7,250.0 Million by 2028 at a rapid and steady CAGR of 16.3% over the forecast period, according to most recent analysis by Emergen Research. The growing demand for cell and gene therapy can be attributed to increasing investments in production capacity expansion for cell and gene therapy. Several contract development & manufacturing organizations and contract manufacturing organizations are making huge investments in the expansion of cell and gene therapy production capacity, anticipating a rise in demand for their services from biopharmaceutical companies that emphasize the development and production of emerging therapeutic technologies.

For instance, in May 2019, CDMO Catalent invested USD 1.20 billion in Paragon Bioservices, a contract development & manufacturing organization involved in developing and producing viral vector development for gene therapy. In April 2019, Paragon Biosciences had commenced its second good manufacturing practices (GMP) gene therapy production facility in Harmans, Maryland, the US, to provide customized manufacturing set-ups to manage the specific requirements for gene therapy products.

Claim Your FREE Sample Copy with Table of content@ https://www.emergenresearch.com/request-sample-form/27

Key Highlights of Report

Check Our Prices@ https://www.emergenresearch.com/select-license/27 Emergen Research has segmented the global cell and gene therapy market in terms of indication, vector type, and region:

Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: http://www.emergenresearch.com/industry-report/cell-and-gene-therapy-market

Take a Look at our Related Reports:

AI-Enabled Medical Imaging Solutions Market By Product (Software, Hardware), By Workflow (Image Acquisition, Image Analysis, Reporting, and Communication), By Therapeutic Application (General Imaging, Specialty Imaging), By Deployment Mode, By Modality, and By Region, Forecasts to 2027

Patient Registry Software Market By Delivery, By Database, By Registry Type, By Function, By Software Type (Integrated, Standalone), By End-use (Government & Third-Party Administrators, Pharmaceutical Companies, Hospitals, Research Centers, Others), and By Region, Forecast to 2027

Operating Room Management Solutions Market By Solution Type (Data management and communication solutions, Operating room supply management solutions, Anesthesia information management solutions, Operating room scheduling solutions, Performance management solutions), By Mode of Deployment (Ob-premises, Cloud-based), By End-Use (Hospitals, Ambulatory surgical centers), and By Region

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: http://www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkedIn | Twitter | Blogs

Read Full Press Release@ http://www.emergenresearch.com/press-release/global-cell-and-gene-therapy-market

Visit link:
Cell and Gene Therapy Market Size to Reach USD 7,250.0 Million by 2028 | Increasing Investments in Production Capacity Expansion for Cell and Gene...

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab -…

Jan. 25, 2021 13:30 UTC

GAITHERSBURG, Md. & BURLINGAME, Calif.--(BUSINESS WIRE)-- Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc.. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a contract development and manufacturing (CDMO) services agreement to accelerate the drug product manufacturing of lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune hyper-response called cytokine storm. Emergent will provide access to manufacturing capacity reserved for and provided by the U.S. government under Humanigens Cooperative Research and Development Agreement (CRADA) with the Department of Defenses (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services. Lenzilumab is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for emergency use authorization (EUA) in the first quarter of 2021.

Under the terms of the agreement, Emergent will provide its integrated CDMO services for the manufacturing of drug product batches to support Humanigens efforts to increase supply of lenzilumab in anticipation of a potential EUA beginning in the first quarter of 2021, including utilization of a new state-of-the-art flex fill line at Emergents Baltimore, MD (Camden) drug product manufacturing facility. This newly expanded facility was built to provide increased capacity and flexibility to support companies in need of clinical and commercial manufacturing capabilities. The parties intend to negotiate a commercial manufacturing services agreement that could include future fill batches for a biologics license application (BLA).

As we continue to advance lenzilumab for patients hospitalized with COVID-19, we are executing on plans to ensure that we have the necessary support for the next phase of our growth. Partnering with leading CDMOs like Emergent BioSolutions to help us build out our manufacturing capacity is a cornerstone to that strategy, said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. The impact of BARDAs support through our CRADA and its public-private CDMO partnership with Emergent is vital to our progress and bringing innovative solutions for patients with COVID-19.

For Emergent, this agreement follows and is in addition to the landmark public-private CDMO partnership between Emergent and BARDA, announced in June 2020, to pave the way for high-priority innovators leveraging reserved capacity at their Drug Substance and Drug Product facilities.

Drug product manufacturing is a hallmark capability of our CDMO services, and we stand ready to harness our expertise to advance lenzilumab, Humanigens COVID-19 therapeutic candidate, said Syed T. Husain, senior vice president and CDMO business unit head at Emergent BioSolutions. Every second counts in the fight against COVID-19, and we are proud that Humanigen trusts us to rapidly deploy our clinical-to-commercial manufacturing operations to fulfill the urgent need for COVID-19 therapeutic options.

This agreement marks Emergents seventh CDMO collaboration with government and industry partners working to deliver COVID-19 vaccine and therapeutic solutions.

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through Emergents specialty products and contract development and manufacturing services, Emergent is dedicated to providing solutions that address public health threats. Through social responsibility, Emergent aims to build healthier and safer communities. Emergent aspires to deliver peace of mind to its patients and customers so they can focus on whats most important in their lives. In working together, Emergent envisions protecting or enhancing 1 billion lives by 2030. For additional information, visit Emergents website and follow Emergent on LinkedIn, Twitter and Instagram.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. Humanigens immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. Humanigen is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com and follow Humanigen on LinkedIn, Twitter and Facebook.

Emergent BioSolutions Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding Emergents ability to advance potential solutions to combat coronavirus disease as well as the anticipated production of the lenzilumab Phase 3 COVID-19 experimental therapeutic candidate at expected levels in the expected timeframe, as well as the potential negotiation of a future commercial manufacturing services agreement that could include fill batches for a BLA, are forward-looking statements. These forward-looking statements are based on current intentions, beliefs and expectations regarding future events. Emergent cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Emergent does not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause Emergents actual results to differ materially from those indicated by such forward-looking statements, including the success of the planned development program; the timing of and ability to obtain and maintain regulatory approvals or authorization for emergency or broader patient use for the product candidate; and Emergents commercialization, marketing and manufacturing capabilities. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Emergents periodic reports filed with the SEC, when evaluating Emergents forward-looking statements.

Humanigen Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although Humanigen management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding the use of lenzilumab to treat patients hospitalized with COVID-19, Humanigens expectations regarding the timeline to file for and obtain EUA, as well as a potential BLA filing, statements regarding Humanigens ability to attain necessary manufacturing support from CDMOs, the potential for an expanded manufacturing services relationship with Emergent, and statements regarding Humanigens beliefs relating to any of the other technologies in Humanigens current pipeline. These forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in Humanigens lack of profitability and need for additional capital to grow Humanigens business; Humanigens dependence on partners to further the development of Humanigens product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory approvals or authorization for emergency or broader patient use for the product candidate and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Humanigen's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. Humanigen undertakes no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005359/en/

Read this article:
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab -...